The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

James R. Cerhan; Matthew J. Maurer; Brian K. Link; Andrew L. Feldman; Thomas M. Habermann; David L. Jaye; W. Richard Burack; Timothy J. McDonnell; Francisco Vega; Jennifer R. Chapman; Sergei Syrbu; Kiran R. Vij; Giorgio Inghirami; John P. Leonard; Leon Bernal-Mizrachi; Umar Farooq; Thomas E. Witzig; George J. Weiner; Yucai Wang; Juan P. Alderuccio; Susan L. Slager; Melissa C. Larson; Shaun M. Riska; Brianna J. Gysbers; Julianne J. Lunde; Tanner W. Reicks; Amy A. Ayers; Colin B. O'Leary; Kathleen J. Yost; Hongfang Liu; Grzegorz S. Nowakowski; Jia Ruan; Dai Chihara; Jean L. Koff; Carla Casulo; Carrie A. Thompson; Jonathon B. Cohen; Brad S. Kahl; Loretta J. Nastoupil; Izidore S. Lossos; Jonathan W. Friedberg; Peter Martin; Christopher R. Flowers

doi:10.1002/ajh.27202

Back

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

Journal article

Peer reviewed

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

James R. Cerhan, Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye, W. Richard Burack, Timothy J. McDonnell, Francisco Vega, Jennifer R. Chapman, …

American journal of hematology, Vol.99(3), pp.408-421

03/2024

DOI: 10.1002/ajh.27202

PMCID: PMC10981429

PMID: 38217361

View Online

Abstract

Abstract To address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/ ). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma ( N = 5883, 76.0%) and germline DNA ( N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes ( N = 1189); and collected quality of life ( N = 5281, 68.3%) and epidemiologic risk factor ( N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.

Details

Title: Subtitle: The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Creators: James R. Cerhan - Mayo Clinic in Florida
Matthew J. Maurer - Mayo Clinic
Brian K. Link - University of Iowa
Andrew L. Feldman - Mayo Clinic
Thomas M. Habermann - Mayo Clinic
David L. Jaye - Emory University
W. Richard Burack - University of Rochester
Timothy J. McDonnell - The University of Texas MD Anderson Cancer Center
Francisco Vega - The University of Texas MD Anderson Cancer Center
Jennifer R. Chapman - Sylvester Comprehensive Cancer Center
Sergei Syrbu - University of Iowa
Kiran R. Vij - Washington University in St. Louis
Giorgio Inghirami - Cornell University
John P. Leonard - Cornell University
Leon Bernal-Mizrachi - Emory University
Umar Farooq - University of Iowa
Thomas E. Witzig - Mayo Clinic
George J. Weiner - University of Iowa
Yucai Wang - Mayo Clinic
Juan P. Alderuccio - Sylvester Comprehensive Cancer Center
Susan L. Slager - Mayo Clinic
Melissa C. Larson - Mayo Clinic
Shaun M. Riska - Mayo Clinic in Arizona
Brianna J. Gysbers - Mayo Clinic
Julianne J. Lunde - Mayo Clinic in Florida
Tanner W. Reicks - Mayo Clinic
Amy A. Ayers - The University of Texas MD Anderson Cancer Center
Colin B. O'Leary - Emory University
Kathleen J. Yost - Mayo Clinic
Hongfang Liu - Mayo Clinic
Grzegorz S. Nowakowski - Mayo Clinic
Jia Ruan - Cornell University
Dai Chihara - The University of Texas MD Anderson Cancer Center
Jean L. Koff - Emory University
Carla Casulo - University of Rochester
Carrie A. Thompson - Mayo Clinic
Jonathon B. Cohen - Emory University
Brad S. Kahl - Washington University in St. Louis
Loretta J. Nastoupil - The University of Texas MD Anderson Cancer Center
Izidore S. Lossos - Sylvester Comprehensive Cancer Center
Jonathan W. Friedberg - Mayo Clinic in Arizona
Peter Martin - Cornell University
Christopher R. Flowers - The University of Texas MD Anderson Cancer Center
Resource Type: Journal article
Publication Details: American journal of hematology, Vol.99(3), pp.408-421
DOI: 10.1002/ajh.27202
PMID: 38217361
PMCID: PMC10981429
NLM abbreviation: Am J Hematol
ISSN: 0361-8609
eISSN: 1096-8652
Grant note: DOI: 10.13039/100000054, name: National Cancer Institute, award: U01 CA195568
Language: English
Electronic publication date: 01/13/2024
Date published: 03/2024
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
Record Identifier: 9984548297902771

Metrics

10 Record Views

19 Times Cited - Web of Science

See more details